title: Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method.
abstract: BACKGROUND
  Pathogen inactivation (PI) technologies are currently licensed for use with platelet (PLT) and plasma components. Treatment of whole blood (WB) would be of benefit to the blood banking community by saving time and costs compared to individual component treatment. However, no paired, pool-and-split study directly assessing the impact of WB PI on the subsequently produced components has yet been reported.
  
  
  METHODS
  In a "pool-and-split" study, WB either was treated with riboflavin and ultraviolet (UV) light or was kept untreated as control. The buffy coat (BC) method produced plasma, PLT, and red blood cell (RBC) components. PLT units arising from the untreated WB study arm were treated with riboflavin and UV light on day of production and compared to PLT concentrates (PCs) produced from the treated WB units. A panel of common in vitro variables for the three types of components was used to monitor quality throughout their respective storage periods.
  
  
  RESULTS
  PCs derived from the WB PI treatment were of significantly better quality than treated PLT components for most variables. RBCs produced from the WB treatment deteriorated earlier during storage than untreated units. Plasma components showed a 3% to 44% loss in activity for several clotting factors.
  
  
  CONCLUSIONS
  Treatment of WB with riboflavin and UV before production of components by the BC method shows a negative impact on all three blood components. PLT units produced from PI-treated WB exhibited less damage compared to PLT component treatment.
authors.affiliation: Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada.|Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.|Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Peter
authors.initials: P
authors.lastname: Schubert
authors.affiliation: Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada.|Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Brankica
authors.initials: B
authors.lastname: Culibrk
authors.affiliation: Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada.|Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Simrath
authors.initials: S
authors.lastname: Karwal
authors.affiliation: Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada.|Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.|Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Katherine
authors.initials: K
authors.lastname: Serrano
authors.affiliation: Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada.|Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.|Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Elena
authors.initials: E
authors.lastname: Levin
authors.affiliation: Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada.|Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Daniel
authors.initials: D
authors.lastname: Bu
authors.affiliation: Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada.|McMaster University, Hamilton, Ontario, Canada.
authors.forename: Varsha
authors.initials: V
authors.lastname: Bhakta
authors.affiliation: Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada.|McMaster University, Hamilton, Ontario, Canada.
authors.forename: William P
authors.initials: WP
authors.lastname: Sheffield
authors.affiliation: TerumoBCT Biotechnologies, Lakewood, Colorado.
authors.forename: Raymond P
authors.initials: RP
authors.lastname: Goodrich
authors.affiliation: Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada.|Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.|Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Dana V
authors.initials: DV
authors.lastname: Devine
mesh_terms: D000255:Adenosine Triphosphate / Q000097:blood; D001769:Blood / Q000187:drug effects* / Q000528:radiation effects*; D058621:Blood Buffy Coat / Q000737:chemistry* / Q000166:cytology*; D001773:Blood Cells / Q000187:drug effects* / Q000528:radiation effects*; D001779:Blood Coagulation Factors / Q000032:analysis; D001786:Blood Glucose / Q000032:analysis; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D001793:Blood Preservation; D058731:Blood Safety / Q000009:adverse effects / Q000379:methods*; D017848:Blood-Borne Pathogens / Q000187:drug effects / Q000528:radiation effects; D048429:Cell Size; D055252:Cell-Derived Microparticles; D015925:Cryopreservation; D004909:Erythrocyte Indices; D006801:Humans; D010949:Plasma; D010976:Platelet Count; D012256:Riboflavin / Q000494:pharmacology*; D014466:Ultraviolet Rays
chemical_list: D001779:Blood Coagulation Factors; D001786:Blood Glucose; D000255:Adenosine Triphosphate; D012256:Riboflavin